Mirum Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $222,503 | $286,326 |
| Short-term investments | 57,812 | — |
| Accounts receivable | 78,286 | 67,968 |
| Inventory | 22,403 | 22,312 |
| Prepaid expenses and other current assets | 11,784 | 10,935 |
| Total current assets | 392,788 | 387,541 |
| Restricted cash | 425 | — |
| Long-term investments | 12,526 | — |
| Property and equipment, net | 1,139 | 706 |
| Operating lease right-of-use assets | 8,675 | 1,284 |
| Intangible assets, net | 249,819 | 252,925 |
| Other assets | 5,382 | 4,165 |
| Total assets | $670,754 | $646,621 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,618 | $7,416 |
| Accrued expenses | 110,224 | 78,544 |
| Operating lease liabilities, current | 1,709 | 1,104 |
| Total current liabilities | 126,551 | 87,064 |
| Operating lease liabilities, noncurrent | 7,972 | 617 |
| Convertible notes payable, net, noncurrent | 308,082 | 306,421 |
| Other liabilities | 2,509 | 3,849 |
| Total liabilities | 445,114 | 397,951 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 48,338,096 and 46,723,143 shares issued and outstanding as of December 31, 2024 and 2023 | 5 | 5 |
| Additional paid-in capital | 870,189 | 803,260 |
| Accumulated deficit | (644,181) | (556,239) |
| Accumulated other comprehensive (loss) income | (373) | 1,644 |
| Total stockholders’ equity | 225,640 | 248,670 |
| Total liabilities and stockholders’ equity | $670,754 | $646,621 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.